BIOLASE (BIOL) Stock Price, News & Analysis

Company Overview

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

Key Stats

• Today's Range: $0.0091 to $0.0120
• 50-Day Range: $0.0080 to $0.0139
• 52-Week Range: $0.02 to $1.94
• Volume: 115,880 shs
• Average Volume: 2.58 million shs
• Market Capitalization: $347.10 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.20
• Consensus Rating: Buy

BIOLASE Stock Analysis - MarketRank™

BIOLASE scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BIOLASE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BIOLASE has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BIOL.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BIOLASE does not currently pay a dividend.

Dividend Growth

BIOLASE does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BIOL.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BIOLASE this week, compared to 0 articles on an average week.

Search Interest

4 people have searched for BIOL on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added BIOLASE to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BIOLASE insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.27% of the stock of BIOLASE is held by insiders.

Percentage Held by Institutions

Only 8.79% of the stock of BIOLASE is held by institutions.

BIOL Stock Analysis - Frequently Asked Questions

How have BIOL shares performed this year?

BIOLASE's stock was trading at $0.0120 at the beginning of 2025. Since then, BIOL shares have decreased by 13.4% and is now trading at $0.0104.

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) issued its quarterly earnings data on Wednesday, November, 10th. The medical technology company reported ($50.00) earnings per share for the quarter, topping the consensus estimate of ($75.00) by $25.00. The medical technology company earned $9.53 million during the quarter. BIOLASE had a negative net margin of 41.65% and a negative trailing twelve-month return on equity of 1,782.73%.

When did BIOLASE's stock split?

BIOLASE shares reverse split on the morning of Friday, July 28th 2023.The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BIOLASE own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BIOLASE investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), SNDL (SNDL), Zomedica (ZOM), NIO (NIO), Exela Technologies (XELA) and Ocugen (OCGN).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/06/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Dental equipment & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BIOL
• Previous Symbol: NASDAQ:BLTI
• CIK: 811240
• Web: www.biolase.com
• Phone: (949) 361-1200
• Fax: 949-273-6677
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.20
• High Stock Price Target: $2.00
• Low Stock Price Target: $0.40
• Potential Upside/Downside: +11,449.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.63 million
• Net Margins: -41.65%
• Pretax Margin: -41.56%
• Return on Equity: -1,782.73%
• Return on Assets: -55.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.71
• Quick Ratio: 0.36

Sales & Book Value

• Annual Sales: $48.83 million
• Price / Sales: 0.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 33,407,000
• Free Float: 33,317,000
• Market Cap: $347.10 thousand
• Optionable: Not Optionable
• Beta: 0.67